Business
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead
About this update from Outlook Therapeutics, Inc.
[{"type":"text","content":"Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service partner for ophthalmic professionals, today announced they have entered into an exclusive commercial distribution agreement for the sale and distribution of LYTENAVA™ (bevacizumab gamma) in the Switzerland market. Under the terms of the agreement, Mediconsult will hold exclusive rights to market, import, distribute and commercialize LYTENAVA™ (bevacizumab gamma) in Switzerland under Outlook Therapeutics’ trademark. Mediconsult will also be responsible for regulatory activities in Switzerland, including seeking and maintaining Marketing Authorization, as well as leading other commercialization efforts in the country. Outlook Therapeutics will retain responsibility for manufacturing, product supply and the maintenance of all related intellectual property. “Switzerland represents an important European market for LYTENAVA™ (bevacizumab gamma), and we are pleased to partner with Mediconsult given their deep ophthalmology expertise and strong track record of successfully registering and commercializing pharmaceutical products in the region,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “This agreement supports our strategy to expand access to LYTENAVA™ (bevacizumab gamma) across Europe while maintaining control over manufacturing and product quality.” Mediconsult AG is a well-established Swiss company with more than 35 years of experience in ophthalmology and a proven history of navigating the Swiss regulatory environment and commercial landscape. The Company brings extensive market knowledge and longstanding relationships with key stakeholders across the ophthalmology community. “We are proud to partner with Outlook Therapeutics to bring LYTENAVA™ (bevacizumab gamma) to patients and ph...